RxDoctor Payments Data

Susan Catchings

Family Medicine · Cary, NCNPI 1679520969

Payments from drug & device makers

$5,673in general payments, 2019–2025

Across 237 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$2K
  • Novo Nordisk$792
  • AbbVie$641
  • Lilly USA, LLC$320
  • Amgen$309
  • AstraZeneca$232
  • plus $2K from 40 others

What the payments were for

  • Consulting fees$1994%
  • Speaking & faculty fees$1,25822%
  • Food & beverage$4,21674%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,673 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$16,807
Medicare patients
47
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$16,494
OzempicSemaglutide11$10,576
SynthroidLevothyroxine Sodium22$2,080
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,186
Levothyroxine Sodium73$784
ValacyclovirValacyclovir Hcl12$611
Rosuvastatin Calcium37$587
Sertraline Hcl15$543
Atorvastatin Calcium30$542
Zolpidem Tartrate44$455
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$391
Famotidine20$384
Tamsulosin Hcl16$348
Gabapentin22$327
Liothyronine Sodium11$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$320$16,49416 claims
Novo NordiskOzempic$792$10,57611 claims
AbbVieSynthroid$641$2,08022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →